Put an Eye on the Weekly Electronic Publication Covering Drug and Device-Based Available Treatments, Current Research and Upcoming Therapies Addressing Eye Disorders
HiTIS - life science & biotech intelligence, a life sciences industry focused competitive intelligence firm, has released the 26th weekly issue of its Eye Care industry competitive intelligence publication: Eye Therapies Competitive Intelligence Weekly (ETCI Weekly).
Paris, France, November 20, 2006 --(PR.com)-- Daily monitoring eye therapies industry news, Eye Therapies Competitive Intelligence Weekly is aimed to provide ophthalmology industry’s executives - and related parties, researchers, physicians, trials investigators, regulators, VCs, etc. - with the most global and focused eye care industry weekly information resource, covering current and future therapies addressing common as well as rare eye diseases such as: cataract, eye injuries, uveitis, retinal disorders, age-related macular degeneration, retinitis pigmentosa, dry eye syndrome, glaucoma, eyelid disorders, optic nerve and optic pathway disorders, conjunctival disorders, refractive error, corneal disorders and eye cancers.
This weekly electronic publication provides immediate and direct access to news including:
- current research status,
- preclinical & clinical development,
- regulatory process from INDs to market approvals,
- manufacturing issues,
- marketed products sales,
- private equity funding,
- IPOs,
- licensing and marketing deals and collaborations (academy and industry),
- mergers & acquisitions,
- financial results,
- events,
- IP and
- litigation.
In brief, the publication covers all phases of the development of eye therapies, from lab bench to patients, via regulatory process.
Eye Therapies Competitive Intelligence Weekly is delivered electronically (per email). Its Microsoft Excel electronic, fully-searchable format includes links to cited companies websites, and direct access to full-text announcements from www.biotech-intelligence.com - a proprietary worldwide news database -, just by clicking headlines.
Christian Girard, ETCI Weekly's Editor, said: "This publication is probably the most comprehensive one covering available or future drugs and devices addressing eye disorders; it is designed to be the must-have information resource for eye therapy industry executives as well as physicians, regulators and other interested parties: VCs, financiers and consultants. From lab research to cutting-edge drugs and devices, including PDT, laser treatments and gene therapy, the publication covers every development, regulatory and marketing phase of these therapies which will represent a serious growth area in the midterm future."
He added "We do not only monitor major industry players actuality. We also monitor emerging companies announcements. Novagali Pharma, Lux Biosciences, GenVec, Fovea Pharmaceuticals, Intelligent Medical Implants, Alchemia, iCo Therapeutics, OculusGen Biomedical, Potentia Pharmaceuticals, Transcend Medical and Sirion Therapeutics - to cite a few ones - are of course also on our radar."
To view a recent issue, go to the following link (or copy/paste it to your browser):
http://www.txpreview.com/ETCI%20Weekly%20-%20%20Y2006%20W43.htm
About HiTIS Competitive Intelligence Publications
HiTIS Competitive Intelligence Publications family includes several focused electronic publications covering therapeutic fields or technologies, like:
Vaccines Competitive Intelligence Weekly,
Neurodegenerative Diseases Tx/Dx Competitive Intelligence Weekly, and
Eye Therapies Competitive Intelligence Weekly
Other similar publications will be announced in due time. Note that specific, customized publications may be developed upon request.
About HiTIS - life science & biotech intelligence
As a quick introduction to HiTIS - life science & biotech intelligence, they are a European competitive intelligence firm offering various intelligence resources and tools: a web-based intelligence platform ( www.biotech-intelligence.com ), customized R&D ePipelines, and a series of competitive intelligence publications.
A free of charge 7-day site trial and reports samples are available on request : see www.txpreview.com for more information
Contact
Christian Girard
Founding Partner & Editor
Mobile +33 (0)6 67 26 60 92
Office +33 (0)1 47 88 23 48
Email christian.girard@biotech-intelligence.com
Web www.biotech-intelligence.com and www.txpreview.com
HiTIS - life science & biotech intelligence
11, rue Madiraa
92400 Courbevoie
France
###
This weekly electronic publication provides immediate and direct access to news including:
- current research status,
- preclinical & clinical development,
- regulatory process from INDs to market approvals,
- manufacturing issues,
- marketed products sales,
- private equity funding,
- IPOs,
- licensing and marketing deals and collaborations (academy and industry),
- mergers & acquisitions,
- financial results,
- events,
- IP and
- litigation.
In brief, the publication covers all phases of the development of eye therapies, from lab bench to patients, via regulatory process.
Eye Therapies Competitive Intelligence Weekly is delivered electronically (per email). Its Microsoft Excel electronic, fully-searchable format includes links to cited companies websites, and direct access to full-text announcements from www.biotech-intelligence.com - a proprietary worldwide news database -, just by clicking headlines.
Christian Girard, ETCI Weekly's Editor, said: "This publication is probably the most comprehensive one covering available or future drugs and devices addressing eye disorders; it is designed to be the must-have information resource for eye therapy industry executives as well as physicians, regulators and other interested parties: VCs, financiers and consultants. From lab research to cutting-edge drugs and devices, including PDT, laser treatments and gene therapy, the publication covers every development, regulatory and marketing phase of these therapies which will represent a serious growth area in the midterm future."
He added "We do not only monitor major industry players actuality. We also monitor emerging companies announcements. Novagali Pharma, Lux Biosciences, GenVec, Fovea Pharmaceuticals, Intelligent Medical Implants, Alchemia, iCo Therapeutics, OculusGen Biomedical, Potentia Pharmaceuticals, Transcend Medical and Sirion Therapeutics - to cite a few ones - are of course also on our radar."
To view a recent issue, go to the following link (or copy/paste it to your browser):
http://www.txpreview.com/ETCI%20Weekly%20-%20%20Y2006%20W43.htm
About HiTIS Competitive Intelligence Publications
HiTIS Competitive Intelligence Publications family includes several focused electronic publications covering therapeutic fields or technologies, like:
Vaccines Competitive Intelligence Weekly,
Neurodegenerative Diseases Tx/Dx Competitive Intelligence Weekly, and
Eye Therapies Competitive Intelligence Weekly
Other similar publications will be announced in due time. Note that specific, customized publications may be developed upon request.
About HiTIS - life science & biotech intelligence
As a quick introduction to HiTIS - life science & biotech intelligence, they are a European competitive intelligence firm offering various intelligence resources and tools: a web-based intelligence platform ( www.biotech-intelligence.com ), customized R&D ePipelines, and a series of competitive intelligence publications.
A free of charge 7-day site trial and reports samples are available on request : see www.txpreview.com for more information
Contact
Christian Girard
Founding Partner & Editor
Mobile +33 (0)6 67 26 60 92
Office +33 (0)1 47 88 23 48
Email christian.girard@biotech-intelligence.com
Web www.biotech-intelligence.com and www.txpreview.com
HiTIS - life science & biotech intelligence
11, rue Madiraa
92400 Courbevoie
France
###
Contact
HiTIS - life science & biotech intelligence
Christian Girard
33 147 882 348
www.txpreview.com
Christian Girard
33 147 882 348
www.txpreview.com
Contact
Categories